TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28659171

Group type: EXPERIMENTAL
Intervention: Endoscopic evacuation
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: Stereotactic aspiration
Number of subjects: 1350

Group type: COMPARATOR
Intervention: Craniotomy
Number of subjects: 1350
Study: 25936338

Group type: EXPERIMENTAL
Intervention: 1100 TMPnano
Number of subjects: 12

Group type: COMPARATOR
Intervention: 1100
Number of subjects: 12

Group type: COMPARATOR
Intervention: 1100 TMP
Number of subjects: 12
Study: 23541975

Group type: EXPERIMENTAL
Intervention: Prolonged dual antiplatelet therapy (DAPT)
Number of subjects: 3560

Group type: EXPERIMENTAL
Intervention: Nuisance bleeding at 1 month
Number of subjects: 3560
Study: 21832181

Group type: EXPERIMENTAL
Intervention: Movement observation of congruent movement stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Movement observation of incongruent movement type
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control stimuli not showing biological motion
Number of subjects: 0
Study: 19488984

Group type: EXPERIMENTAL
Intervention: 25 mg of levosulpiride tablet
Number of subjects: 24
Study: 17096435

Group type: EXPERIMENTAL
Intervention: Sip volumes
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Sip volumes <=2.0 mL
Number of subjects: 505
Study: 15197790

Group type: EXPERIMENTAL
Intervention: 5,6‐dimethylxanthenone‐4‐acetic acid (DMXAA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: combretastatin A4 disodium phosphate (CA4DP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ZD6126
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of vascular-targeting agents with irradiation and other chemotherapeutic agents
Number of subjects: 0
Study: 11708702

Group type: EXPERIMENTAL
Intervention: Plyometric training program
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Traditional weight-training program
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (untrained) group
Number of subjects: 25
Study: 9462904

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High frequency oscillatory ventilation (HFOV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) with adequate lung inflation
Number of subjects: 0
Study: 8778745

Group type: EXPERIMENTAL
Intervention: Nifedipine treatment (10 mg t.i.d. for 5 days)
Number of subjects: 0
Study: 2515939

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 0.03 mg daily
Number of subjects: 250

Group type: COMPARATOR
Intervention: Non-hormonal contraceptives
Number of subjects: 250
Study: 1104284

Group type: EXPERIMENTAL
Intervention: Chewable isosorbide dinitrate
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31543357

Group type: EXPERIMENTAL
Intervention: Acoustic Voice Quality Index (AVQI)
Number of subjects: 90
Study: 31509451

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 150

Group type: COMPARATOR
Intervention: Delayed-treatment (usual care)
Number of subjects: 150
Study: 31266035

Group type: EXPERIMENTAL
Intervention: Delayed Cord Clamping (DCC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Early Cord Clamping (ECC)
Number of subjects: 80
Study: 28787742

Group type: EXPERIMENTAL
Intervention: Azelastine/Fluticasone (AzeFlu)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 26265231

Group type: EXPERIMENTAL
Intervention: Platelet function monitoring with drug adjustment in patients with poor response to antiplatelet therapy
Number of subjects: 1394

Group type: COMPARATOR
Intervention: Conventional strategy without monitoring and drug adjustment
Number of subjects: 1394

Group type: EXPERIMENTAL
Intervention: Intensification of antiplatelet treatment based on platelet function
Number of subjects: 1394

Group type: EXPERIMENTAL
Intervention: CYP2C19 genetic testing
Number of subjects: 1394
Study: 23329559

Group type: EXPERIMENTAL
Intervention: Fast movement training
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Slow movement training
Number of subjects: 1
Study: 21255776

Group type: COMPARATOR
Intervention: Laparoscopy and urine specimens
Number of subjects: 53
Study: 19483514

Group type: EXPERIMENTAL
Intervention: 11-valent pneumococcal conjugate vaccine (11PCV)
Number of subjects: 12191

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12191
Study: 16512940

Group type: EXPERIMENTAL
Intervention: Ferrous bisglycinate as fortificant in bread
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Electrolytic Fe as fortificant in bread
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard unfortified bread
Number of subjects: 160
Study: 12766599

Group type: EXPERIMENTAL
Intervention: 18F‐FDG PET
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 99mTc‐ECD SPECT
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (normal controls)
Number of subjects: 16
Study: 10333376

Group type: EXPERIMENTAL
Intervention: CI‐988 (100 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo CI‐988
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CI‐988 (25 mg)
Number of subjects: 16
Study: 7860338

Group type: EXPERIMENTAL
Intervention: Home visits from the nurse
Number of subjects: 60

Group type: COMPARATOR
Intervention: No home visits
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Type A clients and families
Number of subjects: 60
Study: 1933997

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 241

Group type: COMPARATOR
Intervention: Comparison drug (Doxycycline or Amoxicillin-clavulanate)
Number of subjects: 241
Study: 6214989

Group type: EXPERIMENTAL
Intervention: Moxalactam (1,000 mg intramuscular injection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxalactam (1 g intravenous infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefazolin (0.5 g intravenous infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefazolin (0.5 g)
Number of subjects: 0
Study: 6330478

Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg q.i.d. as i.v. bolus followed by 150 mg orally twice daily
Number of subjects: 380

Group type: COMPARATOR
Intervention: Cimetidine 400 mg q.i.d. intravenously and 1,000 mg daily orally in divided doses
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 380

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 380
Study: 29625605

Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Otorhinolaryngologic surgery without involvement of the oral cavity
Number of subjects: 50
Study: 27841725

Group type: EXPERIMENTAL
Intervention: HPV-16/18 vaccine
Number of subjects: 14838

Group type: COMPARATOR
Intervention: HBV vaccine
Number of subjects: 14838
Study: 25351573

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing during TKA
Number of subjects: 50

Group type: COMPARATOR
Intervention: No patellar resurfacing during TKA
Number of subjects: 50
Study: 22178007

Group type: EXPERIMENTAL
Intervention: In-group member (same university)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Out-group member (another tertiary institution)
Number of subjects: 0
Study: 20431425

Group type: EXPERIMENTAL
Intervention: Fluarix (study vaccine)
Number of subjects: 3325

Group type: COMPARATOR
Intervention: Fluzone (control vaccine)
Number of subjects: 3325

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 3325
Study: 17507739

Group type: EXPERIMENTAL
Intervention: Carbohydrate (1 g CHO/kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 16213293

Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK506)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Cyclosporine (Neoral)
Number of subjects: 123
Study: 12455359

Group type: EXPERIMENTAL
Intervention: BM-91 protocol
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: L-asparaginase
Number of subjects: 687
Study: 10331734

Group type: EXPERIMENTAL
Intervention: Single daily oral rifapentine doses of 150, 300, or 600 mg given on day 1 and again on days 4-10
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Single oral 600 mg dose given on days 1, 4, 7, and 10
Number of subjects: 23
Study: 7558928

Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte macrophage-colony-stimulating factor (rhGM-CSF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 1683337

Group type: EXPERIMENTAL
Intervention: Zotepine (average daily dose of 168 +/- 15 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Zotepine (average daily dose of 241 +/- 70 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Perazine (average daily dose of 348 +/- 09 mg)
Number of subjects: 20
Study: 7325348

Group type: EXPERIMENTAL
Intervention: Epidural morphine during and after the operation
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Postoperative epidural opiate analgesia
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 3.0 mg of morphine
Number of subjects: 22
Study: 31464773

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (a highly purified omega-3 fatty acid, eicosapentaenoic acid ethyl ester)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl
Number of subjects: 0
Study: 29718095

Group type: EXPERIMENTAL
Intervention: Fluorouracil-based chemoradiotherapy (CRT) with oxaliplatin
Number of subjects: 1191

Group type: COMPARATOR
Intervention: Fluorouracil-only CRT
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: NAR score (low)
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: NAR score (intermediate)
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: NAR score (high)
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: NAR score (low vs high)
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: NAR score (low vs intermediate)
Number of subjects: 1191
Study: 27211290

Group type: EXPERIMENTAL
Intervention: Tai Chi intervention (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care (n = 29)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 24047571

Group type: EXPERIMENTAL
Intervention: Neuromuscular control (NMC) programme
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control programme
Number of subjects: 40
Study: 22912941

Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (participative involvement)
Number of subjects: 48
Study: 20482495

Group type: EXPERIMENTAL
Intervention: Mirena IUS
Number of subjects: 103

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 103
Study: 16955065

Group type: EXPERIMENTAL
Intervention: Sforzesco brace (SPoRT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lyon brace (LY)
Number of subjects: 30
Study: 15573395

Group type: EXPERIMENTAL
Intervention: 500 microg IFN-gamma1b
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 1,000 microg IFN-gamma1b
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 12368643

Group type: COMPARATOR
Intervention: Radiographs alone
Number of subjects: 3

Group type: COMPARATOR
Intervention: Radiographs with CT scan
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Radiographs with MRI
Number of subjects: 3
Study: 10430979

Group type: EXPERIMENTAL
Intervention: Captopril therapy
Number of subjects: 108
Study: 8954432

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing
Number of subjects: 170

Group type: COMPARATOR
Intervention: Adhesive skin tapes (Control)
Number of subjects: 170
Study: 1819777

Group type: EXPERIMENTAL
Intervention: CT and thymostimulin Serono (group A)
Number of subjects: 85

Group type: COMPARATOR
Intervention: CT alone (group B)
Number of subjects: 85
Study: 6214237

Group type: EXPERIMENTAL
Intervention: dexamethasonephosphate
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study: 31371115

Group type: EXPERIMENTAL
Intervention: Nebulised iloprost
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29497500

Group type: EXPERIMENTAL
Intervention: Malaria rapid diagnostic tests intervention
Number of subjects: 70
Study: 27119600

Group type: EXPERIMENTAL
Intervention: Artemisia extract (AE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PO)
Number of subjects: 0
Study: 24392793

Group type: EXPERIMENTAL
Intervention: Dynamic supportive-expressive psychotherapy (SET)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Antidepressant medication (ADM)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo (PBO) + clinical management
Number of subjects: 153
Study: 22368219

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous aerobic exercise intervention (EX) (6 d/wk, 60 min/d, 60% to 85% max. heart rate)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Usual lifestyle control (CON)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous aerobic exercise intervention (EX)
Number of subjects: 202
Study: 20585102

Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (TT)
Number of subjects: 40
Study: 17369808

Group type: EXPERIMENTAL
Intervention: Aerobic training (3 sessions per week for 8 weeks, running at 75-80% of HR(max))
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 15752252

Group type: EXPERIMENTAL
Intervention: Reservoir biteguard
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional biteguard
Number of subjects: 86
Study: 12193097

Group type: EXPERIMENTAL
Intervention: Darusentan (30, 100, 300 mg/day)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 9860785

Group type: EXPERIMENTAL
Intervention: Quinaprilat 1.6 microg/min
Number of subjects: 30

Group type: COMPARATOR
Intervention: Enalaprilat 5 microg/min
Number of subjects: 30
Study: 8130044

Group type: EXPERIMENTAL
Intervention: Inhalation anaesthesia with isoflurane and nitrous oxide (group 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Total i.v. anaesthesia with alfentanil and propofol (group 2)
Number of subjects: 20
Study: 2782246

Group type: EXPERIMENTAL
Intervention: Sublingual isosorbide dinitrate (ISDN) in Group C (without sustained ISDN therapy)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sublingual isosorbide dinitrate (ISDN) in Group N (with sustained ISDN therapy)
Number of subjects: 24
Study: 4471965

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 77

Group type: COMPARATOR
Intervention: Tubocurarine (tbc)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 77
Study: 30793465

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 7637

Group type: COMPARATOR
Intervention: No liraglutide
Number of subjects: 7637
Study: 27038191

Group type: EXPERIMENTAL
Intervention: Modified EMDR procedure with eye movements (n = 24)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group with fixed gaze (n = 23)
Number of subjects: 47
Study: 24402203

Group type: EXPERIMENTAL
Intervention: Visual Oddball task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Working Memory task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Working Memory task with high load
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Working Memory task with low load
Number of subjects: 0
Study: 22901904

Group type: EXPERIMENTAL
Intervention: Nondrainage group (n = 60)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Drainage group (n = 61)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 121
Study: 19884365

Group type: EXPERIMENTAL
Intervention: S/GSK1349572 10 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: S/GSK1349572 50 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17828144

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% drops
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.75% drops
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Ropivacaine 1% drops
Number of subjects: 105
Study: 17077653

Group type: EXPERIMENTAL
Intervention: Medication group (n = 27)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Observation group (n = 23)
Number of subjects: 50
Study: 12809357

Group type: EXPERIMENTAL
Intervention: ImmunoGuard (4 mg Andrographolide per tablet, 48 mg daily, taken 3 times of 4 tablets daily for 1 month)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11135797

Group type: EXPERIMENTAL
Intervention: Horticultural and nutrition education intervention in the experimental area (Ilongero)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Experimental area (Ilongero)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Children with helminths
Number of subjects: 236
Study: 8637448

Group type: EXPERIMENTAL
Intervention: Voglibose (0.2 mg tablet before each test meal, 3 tablets per day)
Number of subjects: 16
Study: 7936386

Group type: EXPERIMENTAL
Intervention: GnRH analogue (leuprolide acetate depot)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2452175

Group type: EXPERIMENTAL
Intervention: New biochemical method for assessing tissue damage via urinary excretion of hypoxanthine.
Number of subjects: 26
Study: 30912414

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 48
Study: 28326950

Group type: EXPERIMENTAL
Intervention: Topical 5% lidocaine medicated plaster
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 26265119

Group type: EXPERIMENTAL
Intervention: Transdermal granisetron (GTDS) - one GTDS patch for 7 days
Number of subjects: 196

Group type: COMPARATOR
Intervention: Palonosetron - iv 0.25 mg/day for 1 day
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Transdermal granisetron (GTDS)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Palonosetron
Number of subjects: 196
Study: 23646838

Group type: EXPERIMENTAL
Intervention: Personalized normative feedback (PNF)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Control condition (information about sun protection)
Number of subjects: 263
Study: 21946476

Group type: EXPERIMENTAL
Intervention: GuttaFlow
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: GuttaFlow and accessory gutta‐percha cones without lateral condensation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cold lateral condensation technique
Number of subjects: 80

Group type: COMPARATOR
Intervention: Continuous wave condensation technique
Number of subjects: 80
Study: 19846693

Group type: EXPERIMENTAL
Intervention: Accelerated weightbearing group (group A)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Delayed weightbearing group (group B)
Number of subjects: 31
Study: 16735938

Group type: EXPERIMENTAL
Intervention: Estradiol 0.05 mg/day
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 15592280

Group type: EXPERIMENTAL
Intervention: Raloxifene therapy (60 mg/d every other day for 2 months followed by 60 mg/d)
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Raloxifene therapy
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Slow-dose escalation of raloxifene therapy
Number of subjects: 487

Group type: COMPARATOR
Intervention: Phytohormones or veralipride
Number of subjects: 487
Study: 11452323

Group type: EXPERIMENTAL
Intervention: Hand washing prior to patient physical examination (PPE)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No hand washing prior to patient physical examination (PPE)
Number of subjects: 100
Study: 9119098

Group type: EXPERIMENTAL
Intervention: Axilloscopy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 40
Study: 1648142

Group type: EXPERIMENTAL
Intervention: CAV (cyclophosphamide 800 mg/m2 IV on day 1, doxorubicin 50 mg/m2 IV on day 1, vincristine 1.4 mg/m2 IV on day 1)
Number of subjects: 288

Group type: COMPARATOR
Intervention: PE (cisplatin 80 mg/m2 IV on day 1, etoposide 100 mg/m2 IV on days 1, 3, and 5)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: CAV/PE (alternating CAV and PE)
Number of subjects: 288
Study: 6499602

Group type: EXPERIMENTAL
Intervention: Prednisolone metasulphobenzoate enemas
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose oral prednisolone
Number of subjects: 0
Study: 30945320

Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 120
Study: 30119145

Group type: EXPERIMENTAL
Intervention: Epidural levobupivacaine and morphine before incision (Group 1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Epidural levobupivacaine and morphine after incision (Group 2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Epidural levobupivacaine and morphine at the end of surgery (Group 3)
Number of subjects: 45
Study: 26150037

Group type: EXPERIMENTAL
Intervention: Plasmakinetic urethrotomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cold knife urethrotomy
Number of subjects: 60
Study: 24183364

Group type: EXPERIMENTAL
Intervention: TA-ER (tramadol hydrochloride 75-mg/acetaminophen 650-mg)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study: 21512394

Group type: EXPERIMENTAL
Intervention: Tailored irinotecan and S‐1 therapy (arm A)
Number of subjects: 95

Group type: COMPARATOR
Intervention: S‐1 monotherapy (arm B)
Number of subjects: 95
Study: 19842458

Group type: EXPERIMENTAL
Intervention: ALED-I intervention (16-week Internet-delivered Active Living Every Day program)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control crossover participants
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: ALED-I intervention (8 months follow-up)
Number of subjects: 32
Study: 17714197

Group type: EXPERIMENTAL
Intervention: Sight of chocolate in chocolate cravers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of picture of chocolate with chocolate in the mouth in cravers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pleasantness ratings of chocolate and chocolate-related stimuli in cravers
Number of subjects: 0
Study: 14647957

Group type: EXPERIMENTAL
Intervention: Lorazepam (0.038 mg/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 11440835

Group type: EXPERIMENTAL
Intervention: Vitamin E-coated dialyzer (VE)
Number of subjects: 16

Group type: COMPARATOR
Intervention: High biocompatible synthetic dialyzer (AN)
Number of subjects: 16
Study: 9764132

Group type: EXPERIMENTAL
Intervention: Intensive intervention programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (follow-up study)
Number of subjects: 0